Enanta Pharmaceuticals to Participate in Investor Conferences in September
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA), Hyperfine (HYPR) and Biogen (BIIB)
Enanta Pharmaceuticals, Inc. (ENTA): Caligan Partners' Top Holding Right Now?
Enanta Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Enanta Pharmaceuticals: Hold Rating Amid RSV Pipeline Progress and Financial Caution
Buy Rating Affirmed on Enanta Pharmaceuticals' Promising Drug Pipeline and Strategic Expansion Into Immunology
JP Morgan Maintains Underweight on Enanta Pharma, Lowers Price Target to $10
Evercore ISI Sticks to Their Buy Rating for Enanta Pharmaceuticals (ENTA)
Evercore Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $30
Evercore analyst Liisa Bayko maintains $Enanta Pharmaceuticals(ENTA.US)$ with a buy rating, and maintains the target price at $30.According to TipRanks data, the analyst has a success rate of 45.6%
HC Wainwright & Co. Reiterates Buy on Enanta Pharma, Maintains $27 Price Target
H.C. Wainwright Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $27
H.C. Wainwright analyst Ed Arce maintains $Enanta Pharmaceuticals(ENTA.US)$ with a buy rating, and maintains the target price at $27.According to TipRanks data, the analyst has a success rate of 41.6%
Enanta Pharmaceuticals: Promising Pipeline Progress and a Buy Rating
Express News | Enanta Pharmaceuticals Inc : JP Morgan Cuts Target Price to $10 From $11
JMP Securities Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $22
JMP Securities analyst Roy Buchanan maintains $Enanta Pharmaceuticals(ENTA.US)$ with a buy rating, and maintains the target price at $22.According to TipRanks data, the analyst has a success rate of 2
Buy Rating Affirmed for Enanta Pharmaceuticals Amid Promising Clinical Developments and Robust Financial Health
Enanta Pharma GAAP EPS of -$1.07 Beats by $0.38, Revenue of $18M Beats by $0.84M
Express News | Enanta Pharmaceuticals Q3 Revenue USD 17.971 Million Vs. IBES Estimate USD 17.2 Million
Enanta Pharmaceuticals 3Q Rev $18M >ENTA
Express News | Enanta Pharmaceuticals Q3 Operating Income USD -24.185 Million
Express News | Enanta Pharmaceuticals Q3 Net Income USD -22.658 Million Vs. IBES Estimate USD -31.8 Million